最新の財務諸表(Form-10K)によると、Vycor Medical Incの総資産は$0で、純損失は$0です。
VYCOの主要な財務比率は何ですか?
Vycor Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Vycor Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
Vycor Medical Inc の最大収益セグメントは Banking and Related Activities で、最新の利益発表における収益は 27,909,000 です。地域別に見ると、United States が Vycor Medical Inc の主要市場であり、収益は 27,909,000 です。
Vycor Medical Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Vycor Medical Incの純損失は$0です。
Vycor Medical Incに負債はありますか?
いいえ、Vycor Medical Incの負債は0です。
Vycor Medical Incの発行済株式数は何株ですか?
Vycor Medical Incの総発行済株式数は0株です。
主要データ
前終値
$0.07
始値
$0.07
当日レンジ
$0.07 - $0.07
52週レンジ
$0.0321 - $0.235
取引高
11.0K
平均取引高
17.8K
配当利回り
--
1株当たり利益(TTM)
-0.00
時価総額
$2.3M
VYCOとは何ですか?
Vycor Medical, Inc. engages in the provision of innovative surgical and therapeutic solutions to the medical community. The company is headquartered in Boca Raton, Florida and currently employs 7 full-time employees. The company went IPO on 2009-03-31. The firm designs, develops and markets neurological medical devices and therapies. The firm operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage, such as that caused by a stroke. Vycor Medical’s ViewSite Brain Access System (VBAS) is a next-generation retraction and access system. VBAS is a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system is used in over 300 hospitals in the United States and in numerous countries internationally. NovaVision products include Visual Restoration Therapy (VRT) and NeuroEyeCoach.